Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

INR:8703. casino blackjack split Starting next year, a large number of anti-cancer APIs and rare disease APIs will be subject to zero tariffs! The eighth i ...

INR:8784. mastercard bet365 Innovative therapy targeting dual inflammation-related cytokine pathways received FDA breakthrough therapy designation After GMP, GC ...

INR:6441. rummy 366 CD19 CAR-T cell therapy! Gilead's Yescarta treatment of iNHL has a complete remission rate of 80% Another doctor was suspended, his prescription rig ...

INR:1994. kerala lottery bumper list "Pharmaceutical Speed ​​Reading Club" Many Biogen employees were infected with the new coronavirus, and Pien T ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

INR:4214. what happens if a casino overpays you Gilead announces 2019H1 results, CAR-T therapy Yescarta revenue doubles ...

INR:2379. ph bet online casino Gilead's Yescarta was granted orphan drug status by the FDA and included in the priority review in China! R&D Daily丨ShuoShi ...